Kinase Chemistry – Just a year and a half behind the times.


Posted by kinasepro on August 9, 2007

The news today is that LS-104 is in Ph1 and now owned by Aegera from Lymphosign who in turn licsensed it from HSC. Their portfolio of patent applications suggests the compound is likely a tyrphostin derivative.

LS104 is a novel small molecule tyrosine kinase inhibitor of therapeutically significant kinases including Jak2 and Bcr-Abl…In contrast to marketed kinase inhibitor drugs, LS104 inhibits its targets in a non-ATP-competitive manner



I don’ t know about you but I needed a history lesson to get a handle on these

2 Responses to “LS-104”

  1. Biotech said

    An extended Michael acceptor and dihydroxybenzene in the molecule… no ADMET or tox issues with this compound then…

  2. kinasepro said

    I was thinkin active metabolite yielding a flavanoid…

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: